Potential factors that may hinder the long-term efficacy of ide-cel therapy in multiple myeloma include the loss of BCMA expression over time, high tumor burden resulting in CAR T-cell exhaustion, and the weaker in vivo killing effects of 4-1BB CAR T-cell products [28,29]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.